Zura Bio Limited Share Price & Technical Analysis
ZURA · $4.36 (-1.80%)
Healthcare / Biotechnology
$4.36
-1.80%
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops…
Price chart
Seasonality
May has 1 positive and 3 negative years (last 4 years shown)
-14% return in May, -11% avg return in past 3 year May month.
-13% return in 2026, 49% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 10% | 16% | -9% | -15% | -14% | – | – | – | – | – | – | – | -13% |
| 25 | -24% | -22% | -13% | 15% | -33% | 0% | 40% | 43% | 115% | -12% | -3% | 37% | 143% |
| 24 | -39% | 28% | -30% | 72% | 21% | -35% | 14% | 5% | 0% | 7% | -32% | -17% | -5% |
| 23 | – | – | 89% | -53% | -20% | 44% | -16% | 0% | -4% | -28% | 2% | -4% | 9% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$449.73M
P/E ratio
—
52W high
$7.44
52W low
$0.98
Volume
5,10,985
Beta
0.09
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Zura Bio Limited share price today?
- Zura Bio Limited (ZURA) last traded around $4.36 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ZURA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ZURA. Download the app for real-time alerts.
- How can I analyze Zura Bio Limited stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.